Guillain-Barré syndrome: an update

Area of Science:

• Neurology
• Immunology
• Pathophysiology

Background:

• Guillain-Barré syndrome (GBS) is an acute polyneuropathy with diverse subtypes, including the common demyelinating form and axonal forms (AMAN, AMSAN) prevalent in Asia.
• Axonal GBS subtypes are often linked to Campylobacter jejuni infections and may involve anti-ganglioside antibodies targeting sodium channels.
• While corticosteroids are ineffective, plasmapheresis and intravenous immunoglobulin show established efficacy in randomized trials.

Purpose of the Study:

• To provide a comprehensive update on the epidemiology, clinical manifestations, diagnostic approaches, underlying pathogenesis, and current treatment strategies for Guillain-Barré syndrome.
• To consolidate recent findings on GBS subtypes, particularly axonal forms, and their association with specific infections and antibody profiles.
• To review the established and emerging therapeutic options for GBS, emphasizing treatments with proven efficacy.

Main Methods:

• Literature review of epidemiology, clinical features, diagnosis, pathogenesis, and treatment of Guillain-Barré syndrome.
• Analysis of data from international randomized trials on GBS treatment efficacy.
• Synthesis of current understanding regarding the role of anti-ganglioside antibodies and sodium channel function in GBS pathogenesis.

Main Results:

• Acute inflammatory demyelinating polyradiculoneuropathy is the most common GBS subtype in Western countries (90%).
• Axonal forms (AMAN, AMSAN) are more common in Asia and associated with Campylobacter jejuni infections and specific anti-ganglioside antibodies.
• Plasmapheresis and intravenous immunoglobulin are effective treatments, while corticosteroids are not.

Conclusions:

• GBS management relies on established therapies like plasmapheresis and IVIg, with ongoing research into pathogenesis.
• Understanding GBS subtypes and their specific triggers, such as Campylobacter jejuni and anti-ganglioside antibodies, is crucial for diagnosis and treatment.
• Rapid clinical improvement suggests mechanisms beyond demyelination, potentially involving antibody-mediated sodium channel blockade or cytokine effects.